A candidate aimed at four targets
Celltrion and SCOHIA PHARMA presented the results at TIDES Europe, a conference on next-generation therapeutics held in Amsterdam. CT-G32/SCO-940 is a quadruple agonist designed to act simultaneously on four hormonal pathways:
- GLP-1: involved in appetite and blood sugar control
- GIP: involved in regulating insulin secretion and metabolism
- Glucagon: involved in energy expenditure
- Amylin: contributes to the feeling of fullness
Based on publicly available development information, it is the first obesity drug candidate to combine all four targets in a single treatment.
Results in animals
In tests on diet-induced obese rats, the candidate achieved greater weight loss than retatrutide, a leading experimental triple agonist, at the same dosage. The reduction in lean body mass relative to total weight loss was also smaller, suggesting potential to preserve muscle and other lean tissue during treatment.
















